Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual...
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
March 13, 2024 07:00 ET
|
Pacira BioSciences
-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study --...
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
March 06, 2024 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global...
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
February 29, 2024 08:00 ET
|
Pacira BioSciences
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call...
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
February 22, 2024 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before...
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
February 15, 2024 08:36 ET
|
Pacira BioSciences
– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator – – Significantly greater proportion of opioid-free patients receiving...
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
February 07, 2024 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has...
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
January 04, 2024 17:00 ET
|
Pacira BioSciences
TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference at 8:15 AM PT (11:15...
Pacira Appoints Frank D. Lee as Chief Executive Officer
December 21, 2023 07:30 ET
|
Pacira BioSciences
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- ...